1. Home
  2. BSEM vs RNTX Comparison

BSEM vs RNTX Comparison

Compare BSEM & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioStem Technologies Inc. Common Stock

BSEM

BioStem Technologies Inc. Common Stock

N/A

Current Price

$2.25

Market Cap

76.9M

Sector

Health Care

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

SELL

Current Price

$0.73

Market Cap

65.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BSEM
RNTX
Founded
2006
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.9M
65.3M
IPO Year
2026
2017

Fundamental Metrics

Financial Performance
Metric
BSEM
RNTX
Price
$2.25
$0.73
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
160.3K
★ 325.7K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.16
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$87.68
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.13
$0.69
52 Week High
$5.44
$2.18

Technical Indicators

Market Signals
Indicator
BSEM
RNTX
Relative Strength Index (RSI) 29.75 40.23
Support Level N/A $0.71
Resistance Level $4.12 $0.87
Average True Range (ATR) 0.35 0.06
MACD -0.12 -0.01
Stochastic Oscillator 3.13 4.74

Price Performance

Historical Comparison
BSEM
RNTX

About BSEM BioStem Technologies Inc. Common Stock

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: